Response Biomed Corp RPBIF

RE: How will they follow-up their best quarter eve

[dimar66]

Revenue of the core product, cardio testing is increasing and we know expenses are being cut to the minimum.  Is this enough to save us?  I wonder what the deal is with 3M and Roche, we put so much hope on them and they seem to be failing us, the China market seems to be where the growth is.  If revenue now consists mostly of placing readers this will be low margin and profitability will increase as sales for test cartridges follow.  The spring should see an up-tick in the West Nile sales.  How can we git rid of Kay without going into bankruptcy protection?  Trading in shares has been very quite lately, what does this indicate?